BioInformant

Your Global Leader in Stem Cell Market Research

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

By Leave a Comment

  • Company demonstrates reliable production from multiple biological sources
  • These manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring consistency while maintaining efficiency

TORONTO and HAIFA, Israel, Aug. 15, 2024 — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), announces significant advancements in their manufacturing process of exosomes. Exosomes, which are naturally released by cells, hold immense promise for regenerative medicine and they are at the heart of the Company’s innovative ExoPTEN product, which is being developed for the treatment of acute spinal cord injury and glaucoma. [Read more…]

DigniFI Fecal Incontinence Study: First Participant Treated

By 1 Comment

Pittsburgh, Pa., August 23, 2024 — Cook MyoSite announced that the first participant was treated in the DigniFI Study, a two-stage, randomized, controlled Phase III trial comparing the safety and efficacy of iltamiocel with placebo in the treatment of female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury (OASI). The procedure was performed on August 19 at Segal Trials in Miami, FL, by Principal Investigator Steven E. Chavoustie, MD, FACOG, CCRP. [Read more…]

Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer

By Leave a Comment

Palo Alto, California, August 22, 2024 – I Peace, a pioneering CDMO in induced pluripotent stem (iPS) cells, and iCamuno Biotherapeutics, a biotech company developing iPS cell-based therapies, today announced a significant milestone with the dosing of the first patient in a clinical trial using iPS cell-derived natural killer (iNK) cells for ovarian cancer immunotherapy. iCamuno will lead the trial, which will test the safety and efficacy of NK cells made from I Peace’s cGMP-compliant iPS cells using iCamuno’s NK cell differentiation technology. [Read more…]

Could Cynata’s Cymerus™ Platform Be A Tool for Fighting the Pandemic?

By Leave a Comment

What is the Cymerus™ technology and how could it potentially assist in the battle against Coronavirus cases on a global basis? Cymerus™ is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company.

The proprietary technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs). It then differentiates these cells into mesenchymal stem cells (MSCs). [Read more…]

iPSC Market Leaders and their Business Models

By 2 Comments

Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0